Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 700.97M | $ 674.98M | $ 666.82M | $ 541.53M | $ 429.65M |
| Gross Profit | $ 530.54M | $ 490.31M | $ 467.53M | $ 401.28M | $ 312.32M |
| Operating Income | $ -73.37M | $ 87.67M | $ 60.02M | $ 89.92M | $ 46.35M |
| EBITDA | $ 29.12M | $ 154.59M | $ 140.38M | $ 113.95M | $ 63.51M |
| Net Income | $ -99.56M | $ 41.95M | $ 15.91M | $ 41.98M | $ 145.52M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 484.62M | $ 278.58M | $ 288.65M | $ 656.41M | $ 521.66M |
| Total Assets | $ 1.55B | $ 1.57B | $ 1.68B | $ 2.08B | $ 1.27B |
| Total Debt | $ 638.85M | $ 586.04M | $ 763.39M | $ 1.13B | $ 541.13M |
| Net Debt | $ 362.08M | $ 432.75M | $ 659.25M | $ 543.27M | $ 441.17M |
| Total Liabilities | $ 775.17M | $ 704.26M | $ 906.19M | $ 1.34B | $ 654.83M |
| Stockholders' Equity | $ 778.35M | $ 870.13M | $ 775.01M | $ 730.41M | $ 619.69M |
| Cash Flow | |||||
| Free Cash Flow | $ 178.75M | $ 139.49M | $ 115.20M | $ 79.85M | $ 39.23M |
| Operating Cash Flow | $ 189.39M | $ 154.65M | $ 145.27M | $ 125.72M | $ 77.03M |
| Investing Cash Flow | $ -83.28M | $ 77.54M | $ -225.19M | $ -20.79M | $ -277.61M |
| Financing Cash Flow | $ 17.36M | $ -183.03M | $ -401.53M | $ 380.69M | $ 222.30M |